WT1 protein-specific T-cell therapy (Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center)

N/A

Report date: 2026/02/26 20:00:22

Base Information

Drug NameWT1 protein-specific T-cell therapy (Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center)
Drug Alias NameWT1-targeted T cells - Atara/MSKCCWT1 peptide-specific T-cells - Atara/MSKCCWT1-sensitised T cells - Atara/MSKCCWT1-CTL - Atara/MSKCCWT1-CTL +[6] 
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsMyelodysplastic SyndromesMultiple MyelomaLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer Center
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsMyelodysplastic SyndromesLeukemia

Other Information

ATC CodeN/A
Related LinksN/A